Description

Carvedilol has unique pharmacological profile. It blocks β1, β2, and α1 receptors, used in the management of hypertension and as an adjunct to standard therapy in symptomatic heart failure and also produces vasodilation. In the present study, an attempt has been made to improve drug concentration in the stomach by preparing gastroretentive floating microsphere of carvedilol phosphate to maintain drug levels within a desired range, reduce dosing frequency, Improve patient compliance, improve dissolution and at the site of absorption.Drug molecules presenting no difficulties in their solubility and/or absorption problems are good candidates for oral controlled release formulations but Obstacle may arise for many drugs related to their solubility and/or absorption that may be overcome by formulating Gastroretentive systems which prolong the gastric retention time, improves solubility and hence improves bioavailability for drugs that are less soluble in a high pH environment.